On Friday, October 23, 2015, the Arthritis Advisory Committee (AAC) supported, by a vote of 10-Yes to 4-No, with no abstentions, the safety and efficacy of lesinurad oral tablets, submitted by Ardea Biosciences, Inc. (Ardea), for the treatment of hyperuricemia associated with gout, in combination with a xanthine oxidase inhibitor (XOI). As of June 2012, Ardea has been a wholly-owned subsidiary of AstraZeneca, Inc. (AstraZeneca).
Back to All Events
Earlier Event: October 21Secretary's Advisory Committee on Human Research Protections
Later Event: October 27Pharmacy Compounding Advisory Committee